Guggenheim raised its price target for GH Research PLC to $46. The previous target was $40, and the firm maintained its Buy rating.
The new target implies potential upside of more than 150% from the stock’s current trading price of $18.27.
Guggenheim’s optimism is based on progress with GH001, the company’s inhaled mebufotenin treatment for treatment-resistant depression. The pivotal trial design is largely established, and trial initiation is anticipated in 2027.
Wall Street analysts have a Strong Buy consensus rating on GH Research. Their price targets range from $38 to $55.